In this part of the discussion, Matthew Arango, PharmD, reviews what the DESTINY-Gastric studies have shown about trastuzumab deruxtecan (Enhertu; Daiichi Sankyo, AstraZeneca) in patients with progressive HER2-positive GEA, including response rates, survival benefits, and important safety considerations such as interstitial lung disease.
The panel examined the significant expansion of the Vaccines for Children (VFC) program to over 1000 birthing hospitals, now covering approximately 42% of US births and enabling broader access to respiratory syncytial virus immunizations for newborns.
In this section, Matthew Arango, PharmD, outlines how treatment for HER2-overexpressed gastroesophageal adenocarcinoma (GEA) has traditionally been approached and what distinguishes the major HER2-targeted agents used or emerging in this space.
The expert pharmacists examined the real-world administration errors that have emerged from having multiple respiratory syncytial virus vaccine options with different indications.
Experts debate tracking MS progression beyond EDSS, blending patient-reported symptoms, MRI metrics, and new ICD-10 coding for access.
Ronna Hauser breaks down findings showing that delayed manufacturer refunds under the Medicare Drug Price Negotiation Program are forcing retail pharmacies to minimize high-dollar drug inventory and dip into savings to stay afloat.
The experts express their concerns that current ACIP decisions and guidelines are not backed by "pure science."
Matthew Arango, PharmD, discusses the importance and challenges of HER2 testing in gastroesophageal adenocarcinoma and how biomarker results influence early treatment decisions and patient counseling.
Matthew Arango, PharmD, explains the basics of gastroesophageal adenocarcinoma (GEA), including its risk factors, typical patient profile, diagnostic process, and why cancers of the lower esophagus and stomach are treated as a single disease.
Niagen Bioscience’s NAD research, patents, and clinical trials, plus pharmacist-led supplement education to help consumers choose evidence-based vitamins and supplements.
Experts discuss guideline adoption, therapeutic advances, and team-based care.
To combat vaccine-related misinformation and disinformation, the speakers emphasize the importance of integrated education, community-led advocacy, and proactive outreach.
Explore how limited FDA enforcement impacts vitamins and supplements, as pharmacists push industry transparency with independent testing, COAs, and research-backed quality.
NCPA President Kristen Riddle recaps the organization's Multiple Locations Conference.
The expert pharmacists examined recent shifts in adult respiratory syncytial virus vaccination recommendations, clarifying that all adults 75 years or older should receive the vaccine, and that those aged 50 to 74 years with certain high-risk conditions are also eligible.
Experts weigh EDSS vs patient-reported symptoms in SPMS, urging composite endpoints, MRI insights, and smarter coding to improve therapy access.
The expert pharmacists examined the critical importance of timing in RSV immunization for pregnant individuals and infants, noting that patient conversations often fall at opposite ends of the spectrum, from eager acceptance to strong resistance.
Explore who drives REMS success—from FDA and manufacturers to pharmacists and patients—and how MS therapy routes shape safety, adherence, and workflow.
The second part of this video series highlights thoughts from 4 panelists on shared clinical decision-making and how harmful misinformation is in the health care space.
Consumers seek clinically validated supplements as health information spreads quickly; Niagen Bioscience stresses independent evidence, and pharmacists guide choices using trusted certifications.
Laxmi Mehta, MD, explains how pharmacists can counsel patients on inherited lipid risk factors like lipoprotein(a) and why combining pharmacologic therapy with lifestyle modification is essential for reducing cardiovascular risk.
A group of experts provide insights and answer questions to some of the more pressing topics around changes in vaccine schedules and policies.
Experts discuss practice expansion, guideline updates, and team-based care.
Early electronic health record (EHR) collaboration, scalable clinical infrastructure, and payer strategy planning are essential for pharmacists as cell and gene therapies expand across disease states.
Neoadjuvant pembrolizumab reshapes desmoplastic melanoma care, spotlighting sequence integrity, pharmacist-led toxicity readiness, and oncology networks accelerating rare-cancer immunotherapy innovation.
Wildfire smoke exposure increases asthma morbidity, underscoring the pharmacist’s role in medication preparedness and patient education.
Emerging skin lipid biomarkers precede atopic dermatitis and food allergy, emphasizing barrier restoration as a key therapeutic target for pharmacists.
RSV drives massive U.S. healthcare costs, with hospitalizations fueling most expenses; learn why prevention, vaccines, and antibodies protect adults, infants, and families.
Pharmacist experts explain RSV seasonality, symptoms and high-risk groups, then share practical strategies to close immunization gaps and streamline vaccine delivery.
Remibrutinib is the first oral advanced therapy for adults with chronic spontaneous urticaria (CSU) who remain uncontrolled on high-dose second-generation antihistamines.
